Open in interactive viewer → charts, metric popovers & call review

Medios Trades at Six Times Earnings and Asks the Market to Wait Until 2031

A 6.7% revenue quarter and a Hilfstaxe bullet dodged — but the only question that mattered on the call was why the company isn't buying back its own shares.
ILM1.DE · Earnings Call · 2026-11-10

A quarter that satisfies the spreadsheet but not the share price

Medios AG reported the first nine months of 2026 on 10 November with total revenue of EUR 1.633 billion, up 6.7%, and EBITDA pre of EUR 66.7 million — inside the company's own corridor. On any normal day that is a respectable, boring quarter. It was not a normal day, because the market cap sits near EUR 321 million, the stock trades at roughly six times adjusted earnings by one analyst's arithmetic, and management has just published a 2031 plan to grow the top line from EUR 2.1 billion to EUR 3.1 billion. The tension is not in the numbers. It is in the gap between what the company says it is worth and what the tape says it is worth — a gap the CEO acknowledged without flinching: “we have a solid last quarter with a total revenue for the first 9 months of EUR 1.63 billion and a growth rate of 6.7%” — Thomas Meier, CEO · 2026-11-10. Solid, yes. Rewarded, no.

The Hilfstaxe bullet, and the unit-cost machine that has to absorb it

The structural story is a familiar European healthcare-compounding one: a regulated reimbursement formula moves against you, and the only defence is scale and cost per unit. The Hilfstaxe adjustment landed shortly after the Capital Markets Day and cost roughly EUR 1.2 million that was never in the guidance — and yet guidance was confirmed, explicitly at the low end. CFO Stefan Bauerreis was admirably straight about it: the impact existed, it was not forecast, and the plug is the residual savings from the Avanti Medios! efficiency programme, of which roughly EUR 2.5 million of an expected EUR 5 million is already banked. The gross-profit bridge tells you where the damage lives. Group EBITDA margin slipped to 4.1% from 4.6%, and the cause is not overhead — Bauerreis described the driver as “what is in total this year our major pain point” — Stefan Bauerreis, CFO · 2026-11-10, namely pricing pressure in pharmaceutical supply plus temporarily elevated material costs internationally, including syringe costs that the CEO confirmed are “unchanged. We are working on alternatives, but that will take some time” — Thomas Meier, CEO · 2026-11-10. The genuinely good news sits in patient-specific therapies: revenue up 8.4% for the nine months and 8.2% in the quarter, with the segment back to a 10% EBITDA margin — the level management has been promising for four quarters — helped by closing the Aschaffenburg site, transferring customers into the remaining five labs, and lifting utilisation without adding operating headcount. That is the Avanti playbook working exactly as advertised, and it is the single most important proof point in the release.

The buyback question the CFO could not wave away

What made this call unusual was the Q&A. One analyst did not ask about Hilfstaxe at all; he asked why Medios is not buying back stock today, noting that the EUR 325 million earmarked for M&A to 2031 is roughly 20% larger than the entire market capitalisation. This is the crux of the share price debate, and the CFO's answers are worth reading closely because they are simultaneously reassuring and revealing. On intent, he was unambiguous: buybacks are “our preferred way to go” — Stefan Bauerreis, CFO · 2026-11-10 in the current environment, the valuation gap is agreed, and canceling repurchased shares "will not make too much sense" to avoid. On timing, he retreated behind sequencing and liquidity:

Unfortunately, Medios is not perceived as a DAX corporation, not yet. And therefore, the liquidity in the market is currently, and also historically, not on the best level… would you invest in a company with the only activity say we have no [growth]… but on the other side, are doing just share buyback.

Stefan Bauerreis, CFO · 2026-11-10
That is a fair argument in the abstract and a convenient one in practice. The juxtaposition matters: management is telling investors the equity is cheap while asking them to fund EUR 325 million of acquisitions with that same cheap equity. The analyst's follow-up — that buying back and canceling 30-40% of the shares might beat deploying that capital into M&A — went unanswered in substance.

Cash, Caelo, and what was oddly quiet

The cash flow line is the one number that genuinely deteriorated. Operating cash flow fell to EUR 26.2 million from EUR 52.7 million, with the CFO attributing the gap largely to prior-year one-offs (late supplier payments reversing in Q4 2025) and higher tax payments, and guiding honestly that a full-year figure around EUR 40 million is realistic rather than the historic EUR 50 million-plus. Note also that the Caelo acquisition — billed as the strategic entry into Compounding Essentials — is still excluded from guidance, and its synergies are described as work in progress. The financing plumbing, by contrast, is done: the tranche B RCF was upsized from EUR 100 million to EUR 125 million with an option to EUR 150 million, maturity pushed to November 2031, and the BNP Paribas bridge for Caelo refinanced. So the balance sheet is fine, leverage is below target, goodwill impairment was flatly ruled out for year-end 2026, and the tax rate is expected to fall below 40% next year from above that level now. Nothing here is broken. But the market-relevant question — is this a compounding platform or a value trap with a good slide deck — hinges on two unresolved items: whether the Hilfstaxe pressure is a one-time reset or a recurring ratchet (the CEO expects "price pressures all the time"), and whether capital allocation favours shareholders over empire-building. On the second, the answer given was 'both, in the right structure'. At six times earnings, the market is pricing the possibility that 'the right structure' never quite arrives.